

AMENDMENTS TO CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) Use of a substance for synthesising a drug for the treatment of patients who suffer from a pulmonary disease which is directly or indirectly associated to idiopathic pulmonary disease, hypersensitive pneumonia or diffused panbronchitis, wherein said substance is a peptide or a polypeptide containing the following amino acid sequence:

Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu ~~(SEQ ID NO. 1)~~ (SEQ ID NO. 4).

2. (original) Use according to claim 1, wherein said peptide or a polypeptide further containing following amino acid sequence:

His-Ser-Asp (SEQ ID number 14); Phe-Thr-Asp (SEQ ID NO. 13).

3. (original) Use according to claim 1, wherein said peptide or a polypeptide having following amino acid sequence:

$(A)_n\text{-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-(B)}_m$

wherein A, B is any natural amino acid, A and B are independent of each other; and n, m replacing values from 0-25; n and m are independent of each other.

4. (original) Use according to claim 3, wherein (A)_n has following sequence if n > 2:

(X)_o-Phe-Thr-Asp-(Y)_p;

wherein X, Y is any natural amino acid, X and Y are independently of each other; and o, p is a replacing value from 0-11, o and p are independent of each other.

5. (original) Use according to claim 4, wherein (X)_o has following sequence if o > 2:

(X')_q-His-Ser-Asp-(X'')_r,

wherein X', X'' is any natural amino acid, X' and X'' are independent of each other; and r, q ist a replacing value from 0-4, r and q are independent of each other.

6. (currently amended) Use according to claim 3, wherein the sequence of said peptide or polypeptide belongs to following group:

- (i) Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 4)
- (ii) Phe-Thr-Asp-X¹-X²-X³-X⁴-X⁵-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID NO. 5);
- (iii) Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID NO. 6);
- (iv) Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 7);
- (v) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 9);

- (vi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 10);
- (vii) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-X⁸-X⁹-X¹⁰-X¹¹-(X¹²) (SEQ ID NO. 11);
- (viii) His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (VIP, SEQ ID NO. 1);
- (ix) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu (PACAP-27,
His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-
Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val
-Lys-Asn-Lys (PACAP-38, SEQ ID NO. 2);
- (x) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu X⁸-X⁹-X¹⁰-X¹¹-X¹²-X¹³-X¹⁴-X¹⁵-X¹⁶-X¹⁷-X¹⁸-X¹⁹-X²⁰-X²¹-X²² (SEQ ID NO. 12);
- (xi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys (PACAP-38,
His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-
Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu (PACAP-27, SEQ ID NO. 3);

wherein X¹ - X²² is any naturally occurring amino acid.

7. (currently amended) Use according to claim 1 claims 1 - 6, wherein any said peptide or polypeptide is an analogue or a derivative with the same biological function.

8. (original) Use according to claim 7, wherein any said peptide or polypeptide is in a stabilised form.

9. (currently amended) Use according to claim 1 ~~claims 1-8~~ , wherein said disease is idiopathic pulmonary fibrosis.

10. (currently amended) Use according to claim 1 ~~claims 1-8~~ , wherein said disease is hypersensitive pneumonia.

11. (currently amended) Use according to claim 1 ~~claims 1-8~~ , wherein said disease is diffused panbronchiolitis.

12. (currently amended) Use according to claim 1 ~~claims 1-8~~ , wherein the therapeutically effective peptides are administered as aerosols.

13. (new) Use according to claim 2, wherein said disease is idiopathic pulmonary fibrosis.

14. (new) Use according to claim 2, wherein said disease is hypersensitive pneumonia.

15. (new) Use according to claim 2, wherein the therapeutically effective peptides are administered as aerosols.

16. (new) Use according to claim 3, wherein any said peptide or polypeptide is an analogue or a derivative with the same biological function.

17. (new) Use according to claim 3, wherein said disease is diffused panbronchiolitis.

18. (new) Use according to claim 3, wherein the therapeutically effective peptides are administered as aerosols.